Published in BMJ on May 30, 2013
Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility. Nat Commun (2013) 1.37
Population pharmacokinetics of oseltamivir and oseltamivir carboxylate in obese and non-obese volunteers. Br J Clin Pharmacol (2016) 0.98
Pharmacokinetic-pharmacodynamic determinants of oseltamivir efficacy using data from phase 2 inoculation studies. Antimicrob Agents Chemother (2013) 0.97
Debate Regarding Oseltamivir Use for Seasonal and Pandemic Influenza. Emerg Infect Dis (2016) 0.87
Outcomes of influenza A(H1N1)pdm09 virus infection: results from two international cohort studies. PLoS One (2014) 0.86
Viral and atypical bacterial aetiologies of infection in hospitalised patients admitted with clinical suspicion of influenza in Thailand, Vietnam and Indonesia. Influenza Other Respir Viruses (2015) 0.82
How to approach and treat viral infections in ICU patients. BMC Infect Dis (2014) 0.77
Severe influenza treatment guideline. Korean J Intern Med (2014) 0.77
Efficacy of oseltamivir-peramivir combination therapy compared to oseltamivir monotherapy for Influenza A (H7N9) infection: a retrospective study. BMC Infect Dis (2016) 0.76
Patient-based transcriptome-wide analysis identify interferon and ubiquination pathways as potential predictors of influenza A disease severity. PLoS One (2014) 0.75
Interdisciplinary pharmacometrics linking oseltamivir pharmacology, influenza epidemiology and health economics to inform antiviral use in pandemics. Br J Clin Pharmacol (2017) 0.75
Efficacy and safety of clearing heat and detoxifying injection in the treatment of influenza: a randomized, double-blinded, placebo-controlled trial. Evid Based Complement Alternat Med (2014) 0.75
Double dose oseltamivir for severe influenza--does it help? BMJ (2013) 0.75
Secondary organizing pneumonia following viral pneumonia caused by severe influenza B: a case report and literature reviews. BMC Infect Dis (2017) 0.75
Efficacy and safety of Re-Du-Ning injection in the treatment of seasonal influenza: results from a randomized, double-blinded, multicenter, oseltamivir-controlled trial. Oncotarget (2017) 0.75
Prediction of creatinine clearance from serum creatinine. Nephron (1976) 64.02
Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA (2003) 31.71
Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med (2013) 24.88
Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med (2005) 15.53
A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics (1976) 13.83
Avian influenza A (H5N1) infection in humans. N Engl J Med (2005) 12.95
Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med (2008) 10.27
Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med (2010) 9.90
Seasonal influenza in adults and children--diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis (2009) 6.52
Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma. N Engl J Med (2005) 6.47
Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Euro Surveill (2008) 5.54
Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis (2007) 5.39
Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis (2009) 5.23
Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet (2000) 5.03
Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J (2001) 4.93
Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA (1999) 4.71
Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol (1984) 4.64
Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet (1999) 3.61
Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection. Clin Infect Dis (2010) 3.49
Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother (2003) 3.24
Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies. Ann Intern Med (2012) 3.05
Effectiveness of antiviral treatment in human influenza A(H5N1) infections: analysis of a Global Patient Registry. J Infect Dis (2010) 2.84
The natural viral load profile of patients with pandemic 2009 influenza A(H1N1) and the effect of oseltamivir treatment. Chest (2010) 2.48
Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials. Clin Infect Dis (2011) 1.95
Effects of early oseltamivir therapy on viral shedding in 2009 pandemic influenza A (H1N1) virus infection. Clin Infect Dis (2010) 1.72
Adult hospitalizations for laboratory-positive influenza during the 2005-2006 through 2007-2008 seasons in the United States. J Infect Dis (2010) 1.40
Oral oseltamivir in human experimental influenza B infection. Antivir Ther (2000) 1.39
Factors associated with early hospital discharge of adult influenza patients. Antivir Ther (2007) 1.31
Similarity in pharmacokinetics of oseltamivir and oseltamivir carboxylate in Japanese and Caucasian subjects. J Clin Pharmacol (2007) 1.30
Safety and pharmacokinetics of oseltamivir at standard and high dosages. Int J Antimicrob Agents (2010) 1.29
Early versus late oseltamivir treatment in severely ill patients with 2009 pandemic influenza A (H1N1): speed is life. J Antimicrob Chemother (2011) 1.24
Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antivir Ther (2003) 1.18
Viral shedding in children with influenza virus infections treated with neuraminidase inhibitors. Pediatr Infect Dis J (2005) 1.15
End points for testing influenza antiviral treatments for patients at high risk of severe and life-threatening disease. J Infect Dis (2010) 1.11
Antiviral therapy and outcomes of patients with pneumonia caused by influenza A pandemic (H1N1) virus. PLoS One (2012) 0.97
Pandemic (H1N1) 2009 influenza in hospitalized children in Manitoba: nosocomial transmission and lessons learned from the first wave. Infect Control Hosp Epidemiol (2011) 0.88
A clinical trial of intravenous peramivir compared with oral oseltamivir for the treatment of seasonal influenza in hospitalized adults. Antivir Ther (2012) 0.87
FDA clears new CDC test to detect human influenza. J Environ Health (2008) 0.86
Hemagglutinin 222 variants in pandemic (H1N1) 2009 virus. Emerg Infect Dis (2011) 0.85